[{"data":1,"prerenderedAt":228},["ShallowReactive",2],{"content-route-/en/research/candida-biofilm-rvvc-2025":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":21,"projection":163,"alternates":219},"target","/en/research/candida-biofilm-rvvc-2025","en-US",{"kind":8,"family":8,"sectionKeys":9},"research-summary",[10,11,12,13,14,15,16,17,18,19,20],"bottom-line","why-source-matters","study-population","tested","results","applicability","limitations","contribution","practical-change","funding-conflicts","source",{"kind":8,"title":22,"description":23,"firstPublished":24,"evidenceAsOf":24,"lastUpdated":24,"changeNote":25,"research":26,"relations":63,"body":67},"Candida biofilm findings in recurrent vaginal yeast infection","Isolates from recurrent vaginal yeast infections had higher biomass in vitro; XTT and confocal comparisons were not significant; no treatment was tested.","2026-10-09","Added a contextual summary of a prospective vaginal-isolate study; its assay findings do not establish an in-vivo biofilm, causation, or treatment benefit, and practical guidance is unchanged.",{"sourceId":27,"studyType":28,"population":29,"sampleScale":30,"contribution":31,"contributionRationale":32,"relatedEvidenceMap":33,"funding":34,"conflicts":35,"paperDate":36,"results":37,"applicability":44,"limitations":49,"practicalChange":62},"diaz-navarro-candida-biofilm-rvvc-2025","Prospective single-center observational clinical-isolate cohort with in-vitro biofilm assays","Adults aged 18 years or older with Candida spp. recovered from vaginal swabs at a tertiary teaching hospital in Madrid, Spain; recurrent vulvovaginal candidiasis (RVVC) classification used reported symptomatic episodes and did not verify every episode by culture.","271 patients (19 RVVC and 252 non-RVVC); CV/XTT assays included 18/19 and 238/252 isolates; CLSM included 16/19 RVVC isolates and 16 selected non-RVVC isolates.","contextual","The cohort adds a prospective human vaginal-isolate comparison to the defined-site biofilm evidence. Crystal-violet biomass was higher in the RVVC group, while XTT metabolic activity and the selected confocal-area comparison were not significantly different. These 24-hour in-vitro assays do not measure vaginal biofilm burden in vivo, establish that biofilm causes recurrence, test a disruptor, or change practical guidance.","/en/research/evidence/broad-candida-claims","The study was funded by Fundación Mutua Madrileña (FMM24/01), IiSGM (2022-PI-II-COOPTR-01), and ISCIII/FEDER (PI21/00344). Miguel Servet support (MSII18/00008) supported M. Guembe and (CPII20/00015) supported P. Escribano; M. Díaz-Navarro received ISCIII support (FI22/00022).","JG reported speaking and lecture fees from Pfizer, Gilead Sciences, and Merck Sharp & Dohme UK. The other authors reported no commercial or financial relationships that could be construed as conflicts. One author disclosed Frontiers editorial-board membership at submission and stated it did not affect peer review.","2025-03-27",[38,39,40,41,42,43],"Of 271 patients, 19/271 (7.0%) met the study RVVC-group definition; 55/271 (20.3%) reported at least one recurrence, and the RVVC group reported 65 episodes. The study used at least 3 symptomatic episodes per year, but not every episode had culture confirmation.","Crystal-violet biomass was measured in 18/19 RVVC isolates and 238/252 non-RVVC isolates. Median absorbance was 1.850 (IQR 1.578–2.156) versus 1.426 (1.081–1.823), respectively (p=0.005).","XTT metabolic activity used the same denominators: 18/19 versus 238/252. Median absorbance was 0.184 (IQR 0.116–0.293) versus 0.228 (0.147–0.331) (p=0.253), a nonsignificant difference.","Confocal microscopy measured occupied area in 16/19 RVVC isolates and 16 arbitrarily selected, species-matched non-RVVC isolates. Median area was 13.15% (IQR 8.54–16.49) versus 10.73% (5.88–17.73) (p=0.710), not a statistically significant difference.","C. albicans accounted for 90.0% of isolates overall and 73.7% in the RVVC group versus 91.3% in the non-RVVC group (p=0.029). One abstract sentence reports 73.3%; the Results and Table 1 report 73.7%, used here.","Overall symptom categories did not differ significantly between groups (p=0.258); prior antifungal use was 5/19 versus 33/252 (p=0.160). These are descriptive group comparisons, not treatment effects.",{"appliesTo":45,"doesNotApplyTo":47},[46],"Group-level associations between in-vitro biofilm measurements from vaginal Candida isolates and reported RVVC status in this adult Spanish clinic cohort",[48],"Biofilm burden measured in a person's vagina; an individual diagnosis, prognosis, or explanation for recurrence; treatment failure or antifungal resistance; benefit or safety of a biofilm-disrupting product; broad intestinal or whole-body Candida claims",[50,53,56,59],{"finding":51,"limitation":52},"The study classified 19 patients as RVVC and followed the clinical-isolate cohort at one tertiary hospital in Madrid.","It was a small, single-center observational study without a reported sample-size calculation or prespecified primary outcome; episode classification relied mainly on patient reports and not every episode was culture-confirmed.",{"finding":54,"limitation":55},"Biofilm biomass and metabolic activity were measured after 24 hours using the first recovered isolate per patient; confocal area was measured in 32 isolates.","These in-vitro assays do not measure biofilm in the vagina, establish causation, show diagnostic performance, or test treatment. The non-RVVC confocal subset was arbitrarily selected and species-matched.",{"finding":57,"limitation":58},"CV and XTT assays included 256/271 isolates (18/19 RVVC and 238/252 non-RVVC); confocal microscopy included 16/19 RVVC and 16/252 selected non-RVVC isolates.","Isolates were unavailable for CV/XTT in 15/271 patients, and the smaller confocal subset may not represent either group. E. coli co-isolation was assessed in only 81/271 samples, with no RVVC samples available for that test.",{"finding":60,"limitation":61},"Table 1 reports moderate symptoms in 6/19 RVVC and 37/252 non-RVVC patients, while its total count is inconsistent with those component counts.","Do not infer a total moderate-symptom count from that table. The abstract also has one conflicting C. albicans percentage; the Results and Table 1 report 73.7% for RVVC, used in this summary.","No practical change. The study adds a limited in-vitro association between isolate biomass and reported RVVC status, but does not establish an in-vivo vaginal biofilm, causation, diagnosis, treatment benefit, or a reason to change care.",[64],{"group":65,"route":33,"label":66},"evidence","Evidence map: broad Candida claims",{"type":68,"value":69,"toc":159},"minimark",[70,78,84,90,96,111,117,123,129,135,141],[71,72,74],"content-section",{"section-key":10,"title":73},"Bottom line",[75,76,77],"p",{},"This prospective cohort found higher in-vitro crystal-violet biofilm biomass among vaginal Candida isolates from the RVVC group than the non-RVVC group. XTT activity and the smaller confocal-area comparison were not significantly different, and no treatment was tested.",[71,79,81],{"section-key":11,"title":80},"Why this source matters",[75,82,83],{},"The study connects patient-reported recurrence status with laboratory measurements from vaginal Candida isolates. It adds a prospective clinical-isolate comparison to biofilm research, while keeping the measured phenotype separate from biofilm burden in a person's vagina or any treatment effect.",[71,85,87],{"section-key":12,"title":86},"Study and population",[75,88,89],{},"This prospective observational study enrolled 271 adults with Candida spp. recovered from vaginal swabs at the sexually transmitted diseases consultation service of a tertiary teaching hospital in Madrid, Spain. The median age was 34 years (IQR 26–45). Nineteen patients were classified as having recurrent vulvovaginal candidiasis (RVVC) and 252 as non-RVVC. Participants were enrolled from October 2021 to October 2022 and followed for another year, through October 2023. The RVVC group definition was at least 3 symptomatic episodes in a year, but not every episode was culture-confirmed.",[71,91,93],{"section-key":13,"title":92},"What was tested",[75,94,95],{},"Researchers tested the first vaginal Candida isolate recovered from each patient. Crystal-violet absorbance measured biomass and XTT absorbance measured metabolic activity after 24 hours in a laboratory biofilm model, with triplicate assays. Confocal microscopy measured the area occupied by biofilm in 16 RVVC isolates and 16 arbitrarily selected, species-matched non-RVVC isolates. No biofilm-disrupting product, antifungal regimen, or other intervention was assigned.",[71,97,99,102,105,108],{"section-key":14,"title":98},"Results",[75,100,101],{},"Fifty-five of 271 patients (20.3%) reported at least one recurrence; 19/271 (7.0%) met the study's RVVC-group definition and reported 65 episodes.",[75,103,104],{},"For crystal-violet biomass, 18/19 RVVC isolates had a median absorbance of 1.850 (IQR 1.578–2.156), compared with 1.426 (1.081–1.823) among 238/252 non-RVVC isolates (p=0.005). For XTT metabolic activity, the same 18/19 and 238/252 isolates had medians of 0.184 (0.116–0.293) and 0.228 (0.147–0.331), respectively (p=0.253); this difference was not statistically significant.",[75,106,107],{},"Confocal area was assessed in 16/19 RVVC isolates and 16 selected, species-matched non-RVVC isolates. Median occupied area was 13.15% (IQR 8.54–16.49) versus 10.73% (5.88–17.73) (p=0.710), also not statistically significant. C. albicans accounted for 90.0% of isolates overall; it was reported in 73.7% of RVVC and 91.3% of non-RVVC isolates (p=0.029). One abstract sentence gives 73.3% for the RVVC group, while the Results and Table 1 give 73.7%; this summary uses the Results and Table 1 value.",[75,109,110],{},"The overall symptom comparison was not significant (p=0.258), and prior antifungal use was 5/19 versus 33/252 (p=0.160). Neither comparison estimates a treatment effect.",[71,112,114],{"section-key":15,"title":113},"Applicability",[75,115,116],{},"The findings apply to group-level associations between in-vitro measurements of vaginal Candida isolates and reported RVVC status in this adult, single-center Spanish cohort. They do not show how much biofilm was present in a person's vagina, explain an individual's recurrence, identify treatment failure or resistance, or support broad intestinal or whole-body Candida claims.",[71,118,120],{"section-key":16,"title":119},"Limitations",[75,121,122],{},"Only 19 patients were in the RVVC group, and the study reported no sample-size calculation or prespecified primary outcome. Classification relied mainly on reported symptoms; not every episode was culture-confirmed. CV and XTT assays included 256/271 isolates (18/19 RVVC and 238/252 non-RVVC), while confocal microscopy included 16/19 RVVC isolates and 16/252 arbitrarily selected, species-matched non-RVVC isolates. The 24-hour laboratory measurements are not in-vivo vaginal biofilm measurements. The study did not test a disruptor or treatment and cannot establish cause, diagnosis, prognosis, or treatment benefit. E. coli co-isolation was assessed in only 81/271 samples, with no RVVC samples available for that test. Table 1's total count for moderate symptoms conflicts with its component counts, so no total is inferred.",[71,124,126],{"section-key":17,"title":125},"Contribution to the evidence",[75,127,128],{},"Contextual. The cohort adds a prospective patient-level comparison in which in-vitro crystal-violet biomass was higher among RVVC isolates, but XTT activity and the selected confocal-area comparison were not significantly different. It informs the defined mucosal context without measuring biofilm in vivo or changing the linked map's verdict, evidence level, safety status, or practical action.",[71,130,132],{"section-key":18,"title":131},"Practical change",[75,133,134],{},"No practical change. The study did not evaluate an intervention, diagnostic test, or care route. Its isolate-assay association is not a reason to add a biofilm disruptor or change treatment.",[71,136,138],{"section-key":19,"title":137},"Funding and conflicts",[75,139,140],{},"Funding came from Fundación Mutua Madrileña (FMM24/01), IiSGM (2022-PI-II-COOPTR-01), and ISCIII/FEDER (PI21/00344), with named Miguel Servet and ISCIII support for M. Guembe, P. Escribano, and M. Díaz-Navarro. JG reported speaking and lecture fees from Pfizer, Gilead Sciences, and Merck Sharp & Dohme UK. Other authors reported no commercial or financial relationships that could be construed as conflicts. One author disclosed Frontiers editorial-board membership at submission and stated it did not affect peer review.",[71,142,144],{"section-key":20,"title":143},"Source",[75,145,146,153,154,158],{},[147,148,152],"a",{"href":149,"rel":150},"https://doi.org/10.3389/fmicb.2025.1566171",[151],"nofollow","Read the original publication"," (published 27 March 2025; ",[155,156,157],"em",{},"Frontiers in Microbiology",". 2025;16:1566171).",{"title":160,"searchDepth":161,"depth":161,"links":162},"",2,[],{"sources":164,"claims":169,"safety":218},[165],{"sourceId":27,"title":166,"canonicalId":167,"canonicalUrl":149,"publisher":157,"sourceType":168,"publicationDate":36,"lastChecked":24},"New insights in the role of Candida biofilm in the pathogenesis of recurrent vulvovaginal candidiasis: a prospective clinical study","PMID:40212387; DOI:10.3389/fmicb.2025.1566171","observational-study",[170],{"claimId":171,"exactClaim":172,"outcome":173,"population":174,"verdict":175,"evidenceLevel":176,"rationale":177,"safetyStatus":178,"evidenceAsOf":24,"lastUpdated":24,"status":179,"changeHistory":180,"sources":189},"candida-biofilms-have-defined-clinical-boundaries","Candida can form biofilms in defined device-associated and mucosal infections, but demonstrating this biology in those settings does not establish a hidden intestinal biofilm or broad multisystem Candida syndrome in a person with nonspecific symptoms.","presence and clinical relevance of Candida biofilm in a defined infection, without extrapolation to an unvalidated broad syndrome","people with microbiologically and clinically defined Candida infection, especially device-associated candidiasis, compared with otherwise stable people attributing nonspecific symptoms to an unconfirmed intestinal or whole-body Candida biofilm","supported","moderate","CDC catheter guidance and the IDSA candidiasis guideline recognize Candida adherence, extracellular matrix, reduced antimicrobial susceptibility, and the clinical importance of source control in defined device-associated infection. Current biofilm synthesis also describes mucosal and device models. A prospective single-center cohort found higher in-vitro crystal-violet biomass among vaginal isolates from the group with recurrent vulvovaginal candidiasis (RVVC), while XTT activity and a selected confocal-area comparison were not statistically significant; these isolate assays do not measure vaginal biofilm in vivo. A retrospective oncology-center candidemia cohort adds a patient-outcome association for high-level in-vitro biofilm in the treated subgroup (adjusted HR 6.59, 95% CI 1.87-23.24), but only nine high-level isolates were present overall, the binary comparison was not significant, and the paper's patient/case denominator is unclear. This observational subgroup result does not establish causation or a treatment effect. None of these sources validates nonspecific symptoms as a test for an intestinal biofilm or permits device-associated findings to be transferred to a broad outpatient syndrome.","usual-cautions","active",[181,185],{"date":24,"summary":182,"previousVerdict":175,"currentVerdict":175,"previousEvidenceLevel":176,"currentEvidenceLevel":176,"previousSafetyStatus":178,"currentSafetyStatus":178,"practicalActionChanged":183,"sourceIds":184},"Reviewed the whole source set after adding the prospective vaginal-isolate cohort; higher in-vitro crystal-violet biomass adds defined mucosal context, while the XTT and selected CLSM comparisons were not significant. Verdict, evidence level, safety status, and practical action remain unchanged.",false,[27],{"date":24,"summary":186,"previousVerdict":175,"currentVerdict":175,"previousEvidenceLevel":176,"currentEvidenceLevel":176,"previousSafetyStatus":178,"currentSafetyStatus":178,"practicalActionChanged":183,"sourceIds":187},"Added a retrospective oncology-center candidemia cohort with an imprecise high-biofilm mortality association limited to the treated subgroup; the overall binary comparison was not significant and only nine cases had high-level biofilm. This adds invasive-infection context without establishing causation or changing the verdict, evidence level, safety status, or practical action.",[188],"villanueva-cotrina-biofilm-candidemia-mortality-2024",[190,198,204,211,212],{"title":191,"canonicalId":192,"canonicalUrl":193,"publisher":194,"sourceType":195,"publicationDate":196,"lastChecked":197},"Background Information: Pathogenesis — Guidelines for the Prevention of Intravascular Catheter-Related Infections","CDC catheter guideline pathogenesis","https://www.cdc.gov/infection-control/hcp/intravascular-catheter-related-infection/pathogenesis.html","US Centers for Disease Control and Prevention","guideline","2011-01-01","2026-07-15",{"title":199,"canonicalId":200,"canonicalUrl":201,"publisher":202,"sourceType":195,"publicationDate":203,"lastChecked":197},"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","DOI:10.1093/cid/civ933","https://www.idsociety.org/practice-guideline/candidiasis/","Infectious Diseases Society of America","2016-02-15",{"title":205,"canonicalId":206,"canonicalUrl":207,"publisher":208,"sourceType":209,"publicationDate":210,"lastChecked":197},"Natural-Compound Adjuvants Dismantle Candida Biofilms: Mechanisms, Design Rules, and Biofilm-Aware Pharmacology","PMID:41524898; DOI:10.1007/s00284-025-04713-0","https://pmc.ncbi.nlm.nih.gov/articles/PMC12795885/","Current Microbiology","other","2026-01-12",{"title":166,"canonicalId":167,"canonicalUrl":149,"publisher":157,"sourceType":168,"publicationDate":36,"lastChecked":24},{"title":213,"canonicalId":214,"canonicalUrl":215,"publisher":216,"sourceType":168,"publicationDate":217,"lastChecked":24},"Biofilm formation and increased mortality among cancer patients with candidemia in a Peruvian reference center","PMID:39395965; DOI:10.1186/s12879-024-10044-5","https://pmc.ncbi.nlm.nih.gov/articles/PMC11470705/","BMC Infectious Diseases","2024-10-12",[],[220,223,226],{"rel":221,"hreflang":6,"href":222},"alternate","https://candipedia.org/en/research/candida-biofilm-rvvc-2025/",{"rel":221,"hreflang":224,"href":225},"pl-PL","https://candipedia.org/pl/research/biofilm-candida-nawracajaca-grzybica-pochwy-2025/",{"rel":221,"hreflang":227,"href":222},"x-default",1794951393368]